

HOUSE \_\_\_\_\_ AMENDMENT NO. \_\_\_\_\_

Offered By \_\_\_\_\_

AMEND House Committee Substitute for Senate Substitute No. 2 for Senate Committee  
Substitute for Senate Bill No. 62, Page 3, Section 338.550, Line 16, by inserting after all of said  
section and line, the following:

“376.1257. 1. Any health benefit plan that provides coverage and benefits for cancer  
chemotherapy treatment shall not require a higher co-payment, deductible, or coinsurance amount for  
a prescribed orally administered anticancer medication that is used to kill or slow the growth of  
cancerous cells than what the plan requires for an intravenously administered or injected cancer  
medication that is provided, regardless of formulation or benefit category determination by the health  
carrier administering the health benefit plan.

2. A health carrier shall not achieve compliance with the provisions of this section by  
imposing an increase in co-payment, deductible, or coinsurance amount for an intravenously  
administered or injected cancer chemotherapy agent covered under the health benefit plan.

3. Nothing in this section shall be interpreted to prohibit a health carrier from requiring prior  
authorization or imposing other appropriate utilization controls in approving coverage for any  
chemotherapy.

4. The provisions of this section shall not apply to a supplemental insurance policy, including  
a life care contract, accident-only policy, specified disease policy, hospital policy providing a fixed  
daily benefit only, Medicare supplement policy, long-term care policy, short-term major medical  
policies of six months or less duration, or any other supplemental policy as determined by the director  
of the department of insurance, financial institutions and professional registration.

5. As used in this section, the terms "health benefit plan" and "health carrier" shall have the  
same meanings ascribed to such terms in section 376.1350.

6. Coverage under this section shall be limited to Federal Drug Administration approved  
indications and National Comprehensive Cancer Network recommendations.

7. Coverage under this section may be administered by a specialty pharmacy network.”; and

Further amend said bill by amending the title, enacting clause, and intersectional references  
accordingly.